Ovid Therapeutics, months removed from a crushing clinical trial disappointment, said Wednesday that it is trading its most promising drug for enough cash to fund its ambitions in rare neurological diseases.
In selling its rights to a late-stage treatment to Japanese pharma giant Takeda, Ovid will pocket $196 million up front — an amount that exceeds the company’s entire market value as of Tuesday’s close. Ovid is entitled to as much as $660 million more depending on the drug’s progress, and the company is in line for royalties on future sales of the medicine.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
